We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Beyond Aging: Traumatic Brain Injury and Depression Emerge as Leading Predictors of Dementia in US Veterans

MedXY Editorial Team•Mar 12, 2026•Neurology
Alzheimer's diseaseMillion Veteran ProgramTraumatic Brain Injury

Highlights

  • Traumatic Brain Injury (TBI) and depression were found to nearly triple the 10-year hazard of incident Alzheimer Disease and Related Dementias (ADRD).
  • Alcohol Use Disorder (AUD) remains a potent modifiable risk factor, doubling the risk of dementia in the aging Veteran cohort.
  • Military-specific environmental exposures, including Agent Orange and pyridostigmine bromide tablets, are significantly associated with increased ADRD incidence.
  • Findings from the Million Veteran Program (MVP) provide a high-resolution map for targeted screening and early intervention in high-risk Veteran populations.

Background: The Growing Burden of Dementia in the Veteran Population

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Integrating Plasma p-tau217 and APOE Genotype to Predict Cognitive Decline Across Diverse PopulationsThis pooled analysis of seven multi-ethnic cohorts demonstrates the combined prognostic value of plasma phosphorylated tau 217 concentrations and APOE-ε4 genotype for predicting risk and timing of cognitive impairment, emphasizing biomarkerSep 13, 2026Unraveling Alzheimer’s Disease Progression in Down Syndrome via Blood Proteome DynamicsLongitudinal analysis of blood proteins reveals distinctive trajectories and associations with cognitive decline in adults with Down syndrome, shedding light on Alzheimer’s disease pathophysiology in this high-risk group.Sep 5, 2026Plasma Biomarkers for Neocortical Tau BurdenA multiprotein plasma panel improves detection of advanced neocortical tau pathology in Alzheimer’s disease risk individuals beyond p-tau217 alone, enhancing patient stratification and clinical trial selection.Aug 15, 2026Oral Anticoagulants, Cognition, and Clinical Outcomes in Atrial Fibrillation and Alzheimer’s Disease: Insights from a Swedish Nationwide Study
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
This review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.
Aug 13, 2026
Discriminating Prion Diseases from Alzheimer’s Disease Using Plasma Biomarkers: The Crucial Role of NfL/p-tau217 RatioPlasma phosphorylated tau biomarkers overlap in Alzheimer’s and prion diseases, risking diagnostic confusion. The NfL/p-tau217 ratio emerges as an accurate plasma biomarker to distinguish prion diseases from Alzheimer’s, improving diagnostiJul 14, 2026
Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers: Diagnostic Challenges and Clinical ImplicationsThis review examines the impact of traumatic brain injury on the accuracy of Alzheimer disease blood biomarkers, highlighting reduced diagnostic performance in TBI-affected populations and the implications for clinical interpretation.Jul 1, 2026